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AnalysisFunding in 2012:
‘‘Great Recession’’ Starts toBiteBiomedical research budgets are frozen or falling in developed
countries. Can expansion in developing nations continue as
economic contagion spreads?This time last year, global spending on
biomedical research was holding up
reasonably well (Macilwain, 2011), espe-
cially considering the forlorn state of the
world’s economy. But as 2012 dawns,
the full impact of the great recession is
about to be felt in the laboratory, ac-
cording to an informal Cell survey of
research spending trends in 15 leading
nations.
It is tricky to compare biomedical
research spending across nations. Annual
budgets are at different stages of devel-
opment, and the best published data,
which is collated by the Paris-based
Organization for Economic Cooperation
and Development (OECD), is usually 2–3
years out of date. Although inflation
should also be taken into account,14 Cell 148, January 20, 2012 ª2012 Elseviersalaries account for the bulk of research
costs, and given that they are now frozen
for publicly employed researchers in most
Western nations, agencies do not need
inflation-linked increases to maintain
levels of activity. Accordingly, the antici-
pated changes in spending noted here
do not allow for national inflation rates.
Nonetheless, by trawling through pub-
lished documents and interviewing re-
searchers, officials, and analysts in 15
nations, it is possible to estimate how
global funding for biomedical research is
evolving at the beginning of 2012.
Stimulus Shrinks in the US
A cold wind was set in motion when
Lehman Brothers went bust in October
2008, leading to an economic slowdownInc.across Western nations. Now in 2012,
this economic cooling will hit laboratories,
and it will be felt most fully by life scientists
in the United States, which spends more
on biomedical research than the rest of
the world combined, according to most
assessments.
The $30 billion budget of the National
Institutes of Health (NIH) has basically re-
mained flat over the past 3 years, but it
has maintained its spending power
through a temporary $10 billion supple-
ment for NIH in the stimulus bill signed
by President Barack Obama in February
2009.
Money from that package, which
peaked in 2010 and 2011, will now rapidly
fade away. ‘‘You’re going to go from $3
billion in stimulus funds to a few hundred
million, between 2011 and 2013,’’ says
Howard Garrison, head of policy at the
Federation of American Scientists for
Experimental Biology (FASEB), which
lobbies for biomedical research funding.
At the same time, massive pressure on
overall federal spending will virtually
freeze NIH’s core funding.
On December 15, Congress passed
a core NIH budget for 2012 of $30.7
billion, 1% more than it received in
2011. This is clearly better than the 1.5%
1All currency conversions are based on Yahoo
Finance rates quoted on December 15, 2011.decrease applied to most other federal
spending. However, with $1.5 billion
less in stimulus funds and inflation
slowly eroding spending power, US bio-
medical research faces an unprece-
dented cut of more than 5%, in real terms,
during 2012.
And 2013 is likely to be worse. After
tortuous negotiations this October, aCon-
gressional ‘‘supercommittee’’ failed to
specify cuts in US government spending.
This led Congress to implement a
‘‘sequestration’’ program that will auto-
matically trim all government programs
in 2013 and would cut NIH by another
8%–10%, according to FASEB.
It will be hard for either this Congress or
the one elected in November to muster
majorities to overturn the sequestration.
Commentators believe that Democrats,
in particular, may well block any changes
to it, leaving NIH and other agencies to
bite the bullet. ‘‘Everyone says that
across-the-board cuts are a crude way
of doing things,’’ asserts FASEB’s legisla-
tive director, Jennifer Zeitzer. ‘‘But there
would be political fall-out from tampering
with the sequestration plan.’’
‘‘Whether Democrats or Republicans
are in charge, they are going to have to
get to grips with the deficit. Nobody
sees science as exempt, but what the
magnitude of the cuts will be [in future
years] is anyone’s guess,’’ says Jim
Siedow, a plant biologist and vice-provost
for research at Duke University in North
Carolina. Before the budget deal was
struck, Siedow was planning for either a
decrease or a very small increase in the
57% ‘‘overhead’’ payments that Duke
receives on each NIH grant, which pay
for its laboratories and services, such as
libraries.
Stagnation Spreads across Europe
The general situation in the United States
is being echoed all around the world as
the recession bites. Biomedical research
remains popular, both with the general
public and with fiscal conservatives, who
see it as a prudent investment. But after
an initial rally to protect or even increase
spending on it, the argument for
sustaining biomedical research spending
can get consumed by the general pres-
sure to cut funding (see map).
In Canada, researchers were pleased
that last year’s budget brought CN $100million (US $100 million1) in extra funding
for brain research, but they expect little
good news in 2012. An austerity budget
will be introduced in March, and finance
minister Jim Flaherty has asked all
agencies, including the Canadian Institute
of Health Research and Health Canada,
to plan for cuts of at least 5%. ‘‘They
still say science is important, but it isn’t
ring-fenced,’’ saysPaulDufour, a longtime
adviser on Canadian science programs
based in Quebec.
In Britain, the UK Medical Research
Council is better off than other agencies.
‘‘We’re not in a bad place,’’ says its chief
executive, John Savill. Though funds for
all other fields of science in the UK have
been frozen from 2011 to 2013, the MRC
has been allocated small increases.
On December 5, Prime Minister David
Cameron gave his first speech devoted
to science. He laid out a life sciences
strategy for the UK, which included
various regulatory measures—and no
new money for science. But Savill is not
discouraged: ‘‘The government is
listening to the case we’ve made.’’
The picture is mixed in mainland
Europe. Germany powers ahead while
the othermajor scientific nations retrench.
The 2012 health research budget of
BMBF, the German research and educa-
tion ministry, will grow from E1.27 billion
to E1.38 billion (US $1.8 billion), a rise of
almost 9%. Even there, however,
budgetary pressures are expected to
slow the recent spurt in research
spending by 2013.
France has announced a tiny increase
of 0.4% in the 2012 budget of INSERM,
the main biomedical research agency.
But critics assert that the extra funding
will be entirely consumed by the agency’s
growing pension commitment to its
former staff. ‘‘It’s really a decrease, and
more and more researchers are suffering
because they don’t get support,’’ says
Bertrand Monthubert, a mathematician
at the University of Toulouse and former
head of the grass roots scientists’ group
Sauvons La Recherche.
When economist Mario Monti took
over as Prime Minister of Italy this past
November, his first act was to pass a sear-Cell 14ing austerity budget, in outline. But the
plan hasn’t said yet where spending cuts
will fall, researchers in the country say.
In Spain, researchers are cautiously
optimistic that the new conservative
government will try to protect science,
says Enric Banda, director of the Catalan
Research and Innovation Foundation in
Barcelona.
Australia’s economy has fared better
than most developed countries in the
recession. Under the current 3 year
spending plan, funds for its National
Health and Medical Research Council
(NHMRC) will grow modestly from AU
$850 million to AU $877 million (US $877
million) in the financial year that begins
on April 1.
BRIC-Laying Continues
While most of these old imperial powers
struggle to maintain their spending,
emerging powers are doing much better.
Brazil has a unique tradition of constitu-
tionally tying research spending to a
fixed percentage of the economy. This
strategy has paid handsome dividends
for researchers as their economy has
boomed.
The strongest agency, FAPESP in Sao
Paulo State, will increase its total budget
next year by 12%, from BR $886 million
to BR $993 million (US $540 million),
according to its scientific director, Carlos
Henrique de Brito Cruz. He also says
that federal agencies are growing at a
similar pace. Figures from the federal
government suggest that total annual
spending on health research in Brazil
has doubled since 2005, to BR $1.5
billion (US $810 million) last year.
Biomedical research remains weak in
Russia by any measure, but there have
been promising developments lately,
says Konstantin Severinov, a molecular
biologist with posts at both the Russian
Academy of Sciences (RAS) in Moscow
and Rutgers University in New Jersey.
For instance, a nanotechnology initiative
of US $6 billion offered some support for
life sciences; the Russian government
introduced US $5 million ‘‘megagrants’’
to lure back e´migre´s; and some high-
quality programs, such the Molecular
and Cell Biology program run by Georgii
Georgiev, have evolved within RAS itself.
Nonetheless, budgets next year will be
flat at best, reckons Serverinov.8, January 20, 2012 ª2012 Elsevier Inc. 15
That certainly won’t be the case in
India. A new 5 year plan, which will be
published in February and takes effect in
April, is set to incorporate far bigger
budgets for the two main health research
agencies, the Department of Biotech-
nology (DBT) and the Indian Council of
Medical Research (ICMR). The govern-
ment in Delhi wants its own investments
to catch up with the explosive growth of
private sector pharmaceutical research
by both Indian and foreign firms since
patent reform in 2005. So DBT and
ICMR are seriously pitching for increases
of 40% each from their 2011 budgets of
14 billion (US $280 million) and 6 billion
rupees (US $120 million), respectively—
although some observers think they’ll
settle for a 20% increase.
China appears to be equally dynamic,
but its budget process is so opaque that
OECD and other international bodies
decline to estimate its R&D budgets.
Nevertheless, the Institute of Policy and
Management at the Chinese Academy
of Sciences compiled an exhaustive
survey of Chinese research compiled for
UNESCO. It indicated that total Chinese
public spending on health research was
about 3 billion Yuan in 2008, which would
have doubled to 6 billion Yuan (US $1
billion) last year. Observers believe that
this spending will grow by about 20%
again this year.
Other nations in East Asia continue to
press aheadwith expansion of their health16 Cell 148, January 20, 2012 ª2012 Elsevierresearch efforts. Programs in South Korea
achieved spectacular growth rates for
much of the last decade, but their expan-
sion has slowed over the past 2 years.
The 2012 budget has still to be set; it is
expected to grow modestly.
Health research spending in Japan,
which stood at about Y340 billion (US
$4.4 billion) in 2011, has been stagnant
for several years. But analysts say that it
could increase by as much as 10% in
2012, as the government takes stimulus
measures in response to last March’s
tragic earthquake at Fukashima.
The outlook has also improved some-
what in Singapore. Laboratory scientists
are growing accustomed to new mecha-
nisms that support research performed
in collaboration with industry, according
to George Radda, chair of its BioMedical
Research Council. ‘‘The worry that
people had about how to access these
funds is no longer there,’’ he says. Total
BMRC will grow only slowly, he adds,
but at least it is assured for the next
4 years.
What Will the Repercussions Be?
All of these Eastern efforts should be
seen, however, in the context of the
huge slowdown in the dominant biomed-
ical research power: the United States.
Talking to researchers and officials
around the globe, it is notable that
expectations in North America have
deteriorated sharply over the last year.Inc.They are dire in Europe, too, but actual
research spending there is holding up
better than many feared, at least in the
short term. And bold, medium-term
expansion plans in Brazil, India, and
the Far East must now be qualified by
the fact that the overall economic slow-
down is spreading into the developing
world.
Overall, the picture last year was bleak,
but it has darkened considerably since
then. The word heard most frequently
in interviews for this article was ‘‘grim.’’
By the start of 2013, it will become clearer
if this is just a severe, cyclical setback—
as most scientists, busying themselves
in the lab, prefer to think—or if the great
recession will shake the concept of
large-scale, publicly funded biomedical
research funding to its very core.
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